Elevated antibodies against Epstein–Barr virus among individuals predicted to carry nasopharyngeal carcinoma susceptibility variants Free

Abstract

Epstein–Barr virus (EBV) is an obligatory factor in the development of nasopharyngeal carcinoma (NPC), and anti-EBV IgA antibodies are elevated many years prior to the development of NPC. Nearly all adults are infected with EBV, but only a few develop cancer, suggesting that additional co-factors, including genetic susceptibility, must be required for the disease to manifest. Individuals were selected from the Taiwan Family Study, a cohort of 3389 individuals from NPC multiplex families. Primary analyses were conducted among 671 individuals from 69 pedigrees with the strongest family history of disease (>3 NPC-affected family members). The likelihood that a given family member carried a NPC susceptibility variant was estimated using Mendelian segregation rules, assuming a dominant mode of inheritance. We compared anti-EBV IgA antibody seropositivity between family members predicted to be carriers of NPC-linked genetic variants and those with a lower likelihood of carrying such variants. Obligate carriers of NPC susceptibility variants (100 % predicted probability of harbouring the genetic mutation) were nine-fold more likely to be anti-EBV IgA positive compared to family members predicted not to carry disease-causing variants (OR=9.2; P-trend<0.001). This elevated risk was confirmed in analyses restricted to both unaffected individuals and pedigrees with EBV-related pathway variants identified through exome sequencing. Our data indicate that family members who are more likely to carry NPC susceptibility variants are also more likely to be anti-EBNA1 IgA seropositive. Genetic susceptibility associated with control over this common herpes virus is likely a co-factor in determining which EBV-infected adults develop NPC.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001115
2018-07-05
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/99/9/1268.html?itemId=/content/journal/jgv/10.1099/jgv.0.001115&mimeType=html&fmt=ahah

References

  1. Zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970; 228:1056–1058[PubMed]
    [Google Scholar]
  2. Henle W, Henle G, Ho HC, Burtin P, Cachin Y et al. Antibodies to Epstein–Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst 1970; 44:225–231[PubMed]
    [Google Scholar]
  3. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 2002; 8:594–599 [View Article][PubMed]
    [Google Scholar]
  4. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984; 310:1225–1230 [View Article][PubMed]
    [Google Scholar]
  5. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001; 345:1877–1882 [View Article][PubMed]
    [Google Scholar]
  6. Cao SM, Liu Z, Jia WH, Huang QH, Liu Q et al. Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS One 2011; 6:e19100 [View Article][PubMed]
    [Google Scholar]
  7. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976; 17:1–7 [View Article][PubMed]
    [Google Scholar]
  8. Janeway C. Immunobiology, 7th ed. New York, NY: Garland Science, Taylor & Francis Group; 2008
    [Google Scholar]
  9. Cohen JI. Epstein–Barr virus infection. N Engl J Med 2000; 343:481–492 [View Article][PubMed]
    [Google Scholar]
  10. Chang EHA. Nasopharyngeal cancer. In Shottenfeld, Fraumeni. (editors) Cancer Epidemiology and Prevention 2017
    [Google Scholar]
  11. Bei JX, Su WH, Ng CC, Yu K, Chin YM et al. A GWAS meta-analysis and replication study identifies a novel locus within CLPTM1L/TERT associated with nasopharyngeal carcinoma in individuals of chinese ancestry. Cancer Epidemiol Biomarkers Prev 2016; 25:188–192 [View Article][PubMed]
    [Google Scholar]
  12. Su WH, Hildesheim A, Chang YS. Human leukocyte antigens and epstein-barr virus-associated nasopharyngeal carcinoma: old associations offer new clues into the role of immunity in infection-associated cancers. Front Oncol 2013; 3:299 [View Article][PubMed]
    [Google Scholar]
  13. Tang M, Lautenberger JA, Gao X, Sezgin E, Hendrickson SL et al. The principal genetic determinants for nasopharyngeal carcinoma in China involve the HLA class I antigen recognition groove. PLoS Genet 2012; 8:e1003103 [View Article][PubMed]
    [Google Scholar]
  14. Tse KP, Su WH, Chang KP, Tsang NM, Yu CJ et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. Am J Hum Genet 2009; 85:194–203 [View Article][PubMed]
    [Google Scholar]
  15. Feng BJ, Huang W, Shugart YY, Lee MK, Zhang F et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 2002; 31:395–399 [View Article][PubMed]
    [Google Scholar]
  16. Hu LF, Qiu QH, Fu SM, Sun D, Magnusson K et al. A genome-wide scan suggests a susceptibility locus on 5p 13 for nasopharyngeal carcinoma. Eur J Hum Genet 2008; 16:343–349 [View Article][PubMed]
    [Google Scholar]
  17. Xiong W, Zeng ZY, Xia JH, Xia K, Shen SR et al. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res 2004; 64:1972–1974 [View Article][PubMed]
    [Google Scholar]
  18. Pickard A, Chen CJ, Diehl SR, Liu MY, Cheng YJ et al. Epstein–Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer 2004; 111:117–123 [View Article][PubMed]
    [Google Scholar]
  19. Yu KJ, Hsu WL, Pfeiffer RM, Chiang CJ, Wang CP et al. Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families. Clin Cancer Res 2011; 17:1906–1914 [View Article][PubMed]
    [Google Scholar]
  20. Yu KJ, Gao X, Chen CJ, Yang XR, Diehl SR et al. Association of human leukocyte antigens with nasopharyngeal carcinoma in high-risk multiplex families in Taiwan. Hum Immunol 2009; 70:910–914 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001115
Loading
/content/journal/jgv/10.1099/jgv.0.001115
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited Most Cited RSS feed